We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prevalence of Hypogonadism in Male Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00472940
Recruitment Status : Completed
First Posted : May 14, 2007
Last Update Posted : June 27, 2011
Information provided by:

Study Description
Brief Summary:

Cancer and its complications are common problems. In most cases, this condition has a profound impact on survival and quality of life (QoL). Fatigue, sexual dysfunction, decreased sexual drive, depression and poor appetite are commonly seen in these patients. However, these symptoms also are seen in men with other conditions including those with low testosterone levels.

The objective of this study is to determine the number of male patients with cancer that have low testosterone levels and to establish the relationship between testosterone levels and the symptoms that these patients experience.

Condition or disease
Cancer Hypogonadism

Study Design

Study Type : Observational
Estimated Enrollment : 135 participants
Time Perspective: Cross-Sectional
Official Title: Prevalence of Hypogonadism in Male Cancer Patients
Study Start Date : November 2006
Groups and Cohorts

Outcome Measures

Biospecimen Retention:   Samples Without DNA

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Male subjects with cancer and non-cancer controls

Inclusion Criteria:

  1. Male subjects ≥ 18 years of age with histological diagnosis of cancer for cancer group.
  2. Provide written informed consent prior to screening.
  3. Histological diagnosis of cancer other than non-melanoma skin cancer for the two cancer groups.

Exclusion Criteria:

  1. Concomitant use of GH, Megestrol, Marinol, or any other anabolic agent, appetite stimulant (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feedings, or parenteral nutrition during the 3 months prior to entering the study.
  2. Participation in a clinical trial with investigational agents within 1 month of enrollment.
  3. Prior or current use of other medications that interfere with gonadal axis (androgens, estrogens, anti-androgens, etc).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00472940

United States, Texas
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
Michael Debakey Veterans Affairs Medical Center
Solvay Pharmaceuticals
Principal Investigator: Jose M Garcia, MD Baylor College of Medicine, Michael E. DeBakey VAMC
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jose M Garcia/Staff Physician adn Assistant Professor of Medicine, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00472940     History of Changes
Other Study ID Numbers: H-19709
First Posted: May 14, 2007    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011

Keywords provided by Baylor College of Medicine:

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases